Structural damage progression in active PsA

Save

Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data

Navigating the Path to SLE Remission

Save

Watch rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.

GCA: Case by Case

Save

Dive into 4 hypothetical case studies that reveal the diverse and often complex presentations of giant cell arteritis (GCA). Each case is guided by expert commentary from Dr Michael Putman, where he offers practical insights and clinical pearls to enhance your therapeutic strategies for this multifaceted condition.

Debunked. Expert perspectives on Sjögren’s Disease myths

Save

How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.

Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA

Save

Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor's potential role in managing patients with PsA.

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis

Save

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Lupus Nephritis

Save

View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.

Biomarkers in RA

Save

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.

Treatment goals for RA: Is it time to transition MOAs?

Save

Rheumatologists Dr. Christina Charles-Schoeman and Dr. Manish Jain discuss their approaches to setting and pursuing treatment goals for patients with poorly controlled RA after TNFis

EXXELERATE: New Thoughts on High RF Titer

Save

Two leading rheumatologists share insights into why RF levels are important to consider when identifying treatment options for patients with RA.

Autoimmune Myositis: The Role of the Laboratory in Diagnosis and Phenotyping

Save

Hear from rheumatologist Stanley J. Naides MD, FACP, FACR, as he details the clinical features of autoimmune myositis, the associated phenotypes and autoantibodies, plus the methodologies and testing options to support a myositis diagnosis.

Minimizing Steroids in Lupus

Save

Minimizing steroid use in patients with SLE. Learn more about when, why, and how to taper steroids and listen to experts, Dr Michelle Petri and Dr Leanna Wise, discuss key data and their clinical perspectives on these topics.